The ophthalmic drugs market would grow at a CAGR of 7.96% over the predicted time frame. The market is expected to increase in value from US$ 37.35 Bn in 2022 to US$ 68.93 Bn in 2030.
The on ophthalmic drugs Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.
Download Free Sample@ https://www.precedenceresearch.com/sample/2441
A recent report provides crucial insights along with application based and forecast information in the Global Ophthalmic drugs Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Ophthalmic drugs market.
A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.
Companies and Manufacturers Covered
The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Ophthalmic drugs market are included as given below:
Ophthalmic drugs Market Key Players
- Johnson & Johnson services
- Novartis AG
- Bausch Health
- Santen pharmaceutical company limited
- Pfizer Inc.
Market Segments
By Disease
- Eye Allergy
- Eye Infection
- Glaucoma
- Retinal Disorders
- Dry Eye
- Others
By Drug Class
- Anti-Allergy
- Anti-Inflammatory
- Antiglaucoma
- Anti-VEGF Agents
By Dosage
- Eye Solutions
- Gels
- Capsules
- Eye Drops
- Ointments
By Administration
- Systematic
- Topical
- Local Ocular
By Product
- Prescription Drugs
- Over-the-Counter-Drugs
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
Report Objectives
- To define, describe, and forecast the global ophthalmic drugs market based on product, and region
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the ophthalmic drugs market
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Ophthalmic Drugs Market
5.1. COVID-19 Landscape: Ophthalmic Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Ophthalmic Drugs Market, By Disease
8.1. Ophthalmic Drugs Market, by Disease, 2022-2030
8.1.1. Eye Allergy
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Eye Infection
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Glaucoma
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Retinal Disorders
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Dry Eye
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Ophthalmic Drugs Market, By Drug Class
9.1. Ophthalmic Drugs Market, by Drug Class, 2022-2030
9.1.1. Anti-Allergy
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Anti-Inflammatory
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Antiglaucoma
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Anti-VEGF Agents
9.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Ophthalmic Drugs Market, By Dosage
10.1. Ophthalmic Drugs Market, by Dosage, 2022-2030
10.1.1. Eye Solutions
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Gels
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Dessert
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Eye Drops
10.1.4.1. Market Revenue and Forecast (2017-2030)
10.1.5. Ointments
10.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Ophthalmic Drugs Market, By Administration
11.1. Ophthalmic Drugs Market, by Administration, 2022-2030
11.1.1. Systematic
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Topical
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Local Ocular
11.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Ophthalmic Drugs Market, By Product
12.1. Ophthalmic Drugs Market, by Product, 2022-2030
12.1.1. Prescription Drugs
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Over-the-Counter-Drugs
12.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Ophthalmic Drugs Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Disease (2017-2030)
13.1.2. Market Revenue and Forecast, by Drug Class (2017-2030)
13.1.3. Market Revenue and Forecast, by Dosage (2017-2030)
13.1.4. Market Revenue and Forecast, by Administration (2017-2030)
13.1.5. Market Revenue and Forecast, by Product (2017-2030)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Disease (2017-2030)
13.1.6.2. Market Revenue and Forecast, by Drug Class (2017-2030)
13.1.6.3. Market Revenue and Forecast, by Dosage (2017-2030)
13.1.6.4. Market Revenue and Forecast, by Administration (2017-2030)
13.1.6.5. Market Revenue and Forecast, by Product (2017-2030)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Disease (2017-2030)
13.1.7.2. Market Revenue and Forecast, by Drug Class (2017-2030)
13.1.7.3. Market Revenue and Forecast, by Dosage (2017-2030)
13.1.7.4. Market Revenue and Forecast, by Administration (2017-2030)
13.1.7.5. Market Revenue and Forecast, by Product (2017-2030)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Disease (2017-2030)
13.2.2. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2.3. Market Revenue and Forecast, by Dosage (2017-2030)
13.2.4. Market Revenue and Forecast, by Administration (2017-2030)
13.2.5. Market Revenue and Forecast, by Product (2017-2030)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Disease (2017-2030)
13.2.6.2. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2.6.3. Market Revenue and Forecast, by Dosage (2017-2030)
13.2.7. Market Revenue and Forecast, by Administration (2017-2030)
13.2.8. Market Revenue and Forecast, by Product (2017-2030)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Disease (2017-2030)
13.2.9.2. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2.9.3. Market Revenue and Forecast, by Dosage (2017-2030)
13.2.10. Market Revenue and Forecast, by Administration (2017-2030)
13.2.11. Market Revenue and Forecast, by Product (2017-2030)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Disease (2017-2030)
13.2.12.2. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2.12.3. Market Revenue and Forecast, by Dosage (2017-2030)
13.2.12.4. Market Revenue and Forecast, by Administration (2017-2030)
13.2.13. Market Revenue and Forecast, by Product (2017-2030)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Disease (2017-2030)
13.2.14.2. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2.14.3. Market Revenue and Forecast, by Dosage (2017-2030)
13.2.14.4. Market Revenue and Forecast, by Administration (2017-2030)
13.2.15. Market Revenue and Forecast, by Product (2017-2030)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Disease (2017-2030)
13.3.2. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3.3. Market Revenue and Forecast, by Dosage (2017-2030)
13.3.4. Market Revenue and Forecast, by Administration (2017-2030)
13.3.5. Market Revenue and Forecast, by Product (2017-2030)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Disease (2017-2030)
13.3.6.2. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3.6.3. Market Revenue and Forecast, by Dosage (2017-2030)
13.3.6.4. Market Revenue and Forecast, by Administration (2017-2030)
13.3.7. Market Revenue and Forecast, by Product (2017-2030)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Disease (2017-2030)
13.3.8.2. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3.8.3. Market Revenue and Forecast, by Dosage (2017-2030)
13.3.8.4. Market Revenue and Forecast, by Administration (2017-2030)
13.3.9. Market Revenue and Forecast, by Product (2017-2030)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Disease (2017-2030)
13.3.10.2. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3.10.3. Market Revenue and Forecast, by Dosage (2017-2030)
13.3.10.4. Market Revenue and Forecast, by Administration (2017-2030)
13.3.10.5. Market Revenue and Forecast, by Product (2017-2030)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Disease (2017-2030)
13.3.11.2. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3.11.3. Market Revenue and Forecast, by Dosage (2017-2030)
13.3.11.4. Market Revenue and Forecast, by Administration (2017-2030)
13.3.11.5. Market Revenue and Forecast, by Product (2017-2030)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Disease (2017-2030)
13.4.2. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4.3. Market Revenue and Forecast, by Dosage (2017-2030)
13.4.4. Market Revenue and Forecast, by Administration (2017-2030)
13.4.5. Market Revenue and Forecast, by Product (2017-2030)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Disease (2017-2030)
13.4.6.2. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4.6.3. Market Revenue and Forecast, by Dosage (2017-2030)
13.4.6.4. Market Revenue and Forecast, by Administration (2017-2030)
13.4.7. Market Revenue and Forecast, by Product (2017-2030)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Disease (2017-2030)
13.4.8.2. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4.8.3. Market Revenue and Forecast, by Dosage (2017-2030)
13.4.8.4. Market Revenue and Forecast, by Administration (2017-2030)
13.4.9. Market Revenue and Forecast, by Product (2017-2030)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Disease (2017-2030)
13.4.10.2. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4.10.3. Market Revenue and Forecast, by Dosage (2017-2030)
13.4.10.4. Market Revenue and Forecast, by Administration (2017-2030)
13.4.10.5. Market Revenue and Forecast, by Product (2017-2030)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Disease (2017-2030)
13.4.11.2. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4.11.3. Market Revenue and Forecast, by Dosage (2017-2030)
13.4.11.4. Market Revenue and Forecast, by Administration (2017-2030)
13.4.11.5. Market Revenue and Forecast, by Product (2017-2030)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Disease (2017-2030)
13.5.2. Market Revenue and Forecast, by Drug Class (2017-2030)
13.5.3. Market Revenue and Forecast, by Dosage (2017-2030)
13.5.4. Market Revenue and Forecast, by Administration (2017-2030)
13.5.5. Market Revenue and Forecast, by Product (2017-2030)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Disease (2017-2030)
13.5.6.2. Market Revenue and Forecast, by Drug Class (2017-2030)
13.5.6.3. Market Revenue and Forecast, by Dosage (2017-2030)
13.5.6.4. Market Revenue and Forecast, by Administration (2017-2030)
13.5.7. Market Revenue and Forecast, by Product (2017-2030)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Disease (2017-2030)
13.5.8.2. Market Revenue and Forecast, by Drug Class (2017-2030)
13.5.8.3. Market Revenue and Forecast, by Dosage (2017-2030)
13.5.8.4. Market Revenue and Forecast, by Administration (2017-2030)
13.5.8.5. Market Revenue and Forecast, by Product (2017-2030)
Chapter 14. Company Profiles
14.1. Johnson & Johnson services
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Novartis AG
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Bausch Health
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Santen pharmaceutical company limited
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Pfizer Inc.
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
0 Comments